- Home
- PLUR vs ANTX Comparison
PLUR vs ANTX Comparison
Compare PLUR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- ANTX
- Stock Information
- Founded
- PLUR 2001
- ANTX 2017
- Country
- PLUR Israel
- ANTX United States
- Employees
- PLUR N/A
- ANTX N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLUR Health Care
- ANTX Health Care
- Exchange
- PLUR Nasdaq
- ANTX Nasdaq
- Market Cap
- PLUR 36.9M
- ANTX 34.4M
- IPO Year
- PLUR N/A
- ANTX 2022
- Fundamental
- Price
- PLUR $3.95
- ANTX $1.07
- Analyst Decision
- PLUR Strong Buy
- ANTX Buy
- Analyst Count
- PLUR 1
- ANTX 2
- Target Price
- PLUR $12.00
- ANTX $2.00
- AVG Volume (30 Days)
- PLUR 52.1K
- ANTX 93.7K
- Earning Date
- PLUR 11-12-2025
- ANTX 11-12-2025
- Dividend Yield
- PLUR N/A
- ANTX N/A
- EPS Growth
- PLUR N/A
- ANTX N/A
- EPS
- PLUR N/A
- ANTX N/A
- Revenue
- PLUR $1,326,000.00
- ANTX N/A
- Revenue This Year
- PLUR $97.38
- ANTX N/A
- Revenue Next Year
- PLUR $293.97
- ANTX N/A
- P/E Ratio
- PLUR N/A
- ANTX N/A
- Revenue Growth
- PLUR 121.74
- ANTX N/A
- 52 Week Low
- PLUR $3.22
- ANTX $1.01
- 52 Week High
- PLUR $7.13
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- PLUR 48.02
- ANTX 38.11
- Support Level
- PLUR $3.50
- ANTX $1.13
- Resistance Level
- PLUR $4.12
- ANTX $1.17
- Average True Range (ATR)
- PLUR 0.37
- ANTX 0.05
- MACD
- PLUR 0.03
- ANTX -0.01
- Stochastic Oscillator
- PLUR 36.83
- ANTX 19.05
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.